OPKO Health, Inc. (OPK)
OPK Stock Price Chart
Explore OPKO Health, Inc. interactive price chart. Choose custom timeframes to analyze OPK price movements and trends.
OPK Company Profile
Discover essential business fundamentals and corporate details for OPKO Health, Inc. (OPK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Nov 1995
Employees
3.00k
Website
https://www.opko.comCEO
Phillip Frost
Description
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
OPK Financial Timeline
Browse a chronological timeline of OPKO Health, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.08, while revenue estimate is $131.23m.
Earnings released on 28 Apr 2026
EPS came in at -$0.07 matching the estimated -$0.07, while revenue for the quarter reached $124.20m , missing expectations by -4.84%.
Earnings released on 26 Feb 2026
EPS came in at -$0.04 surpassing the estimated -$0.07 by +42.86%, while revenue for the quarter reached $148.50m , beating expectations by +6.26%.
Earnings released on 29 Oct 2025
EPS came in at $0.03 surpassing the estimated -$0.02 by +250.00%, while revenue for the quarter reached $151.67m , beating expectations by +8.52%.
Earnings released on 31 Jul 2025
EPS came in at -$0.19 falling short of the estimated -$0.12 by -58.33%, while revenue for the quarter reached $156.81m , missing expectations by -5.39%.
Earnings released on 30 Apr 2025
EPS came in at -$0.10 falling short of the estimated -$0.06 by -66.67%, while revenue for the quarter reached $149.95m , missing expectations by -9.50%.
Earnings released on 27 Feb 2025
EPS came in at $0.01 surpassing the estimated -$0.08 by +112.50%, while revenue for the quarter reached $183.64m , beating expectations by +18.16%.
Earnings released on 7 Nov 2024
EPS came in at $0.03 surpassing the estimated -$0.10 by +130.00%, while revenue for the quarter reached $173.63m , beating expectations by +11.72%.
Earnings released on 7 Aug 2024
EPS came in at -$0.01 surpassing the estimated -$0.09 by +88.89%, while revenue for the quarter reached $182.19m , missing expectations by -1.62%.
Earnings released on 7 May 2024
EPS came in at -$0.12 falling short of the estimated -$0.09 by -33.33%, while revenue for the quarter reached $173.69m , missing expectations by -5.08%.
Earnings released on 27 Feb 2024
EPS came in at -$0.09 matching the estimated -$0.09, while revenue for the quarter reached $181.90m , beating expectations by +2.46%.
Earnings released on 6 Nov 2023
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $178.60m , beating expectations by +2.19%.
Earnings released on 3 Aug 2023
EPS came in at -$0.03 surpassing the estimated -$0.07 by +57.14%, while revenue for the quarter reached $265.42m , beating expectations by +45.41%.
Earnings released on 3 May 2023
EPS came in at -$0.02 surpassing the estimated -$0.07 by +71.43%, while revenue for the quarter reached $237.60m , beating expectations by +22.89%.
Earnings released on 23 Feb 2023
EPS came in at -$0.11 matching the estimated -$0.11, while revenue for the quarter reached $185.40m , beating expectations by +10.22%.
Earnings released on 8 Nov 2022
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%, while revenue for the quarter reached $179.74m , missing expectations by -2.05%.
Earnings released on 4 Aug 2022
EPS came in at -$0.04 falling short of the estimated -$0.00 by -1.85k%, while revenue for the quarter reached $309.89m , missing expectations by -5.19%.
Earnings released on 9 May 2022
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $329.22m , missing expectations by -1.02%.
Earnings released on 24 Feb 2022
EPS came in at -$0.11 falling short of the estimated -$0.02 by -450.00%, while revenue for the quarter reached $401.30m , beating expectations by +21.67%.
Earnings released on 28 Oct 2021
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $385.81m , beating expectations by +29.11%.
Earnings released on 29 Jul 2021
EPS came in at -$0.03 falling short of the estimated -$0.01 by -155.54%, while revenue for the quarter reached $442.41m , meeting expectations.
OPK Stock Performance
Access detailed OPK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
